You are here

St. Jude Children’s Research Hospital

262 Danny Thomas Place
Memphis, TN 38105
United States

Lay Summary: Wilms tumor is the most common pediatric kidney cancer. The best predictor of clinical outcome for Wilms tumor patients is how their tumor looks under the microscope (histology). The majority of Wilms tumor patients have favorable histology tumors that respond to surgery, chemotherapy, and radiation. These tumors are usually called triphasic tumors because they contain three main cell types--epithelial cells, blastemal cells, and stromal cells.

Lay Summary: This project will perform single-cell analysis of tumor cells and tumor microenvironment cells in 30 cases of acute lymphoblastic leukemia (ALL). The goal is to identify tumor intrinsic and microenvironmental determinants of tumor formation and progression.

Background

Pediatric solid tumors arise during the development of diverse tissues such as bone, muscle and adrenal gland. The tumor cells maintain many features of the normal tissue where they develop including the developmental hierarchy. As a result, cells within an individual patient's tumor has features of different developmental stages. This tumor heterogeneity is important because, in some patients, a subset of those cells survive treatment and contribute to disease relapse which is often fatal.

This grant supported research to understand how the bone marrow microenvironment influence the response of acute lymphoblastic leukemia cells to drug treatment. We used multiple laboratory approaches and identified multiple new proteins and cellular pathways that mediate drug resistance. We also identified a population of leukemia cells that acquire stromal-like properties on engagement with bone marrow stroma. We used this information ro identify and validate a new therapeutic approach to overcome resistance, which is potentially translatable to the clinic.

Osteosarcoma is a malignant and aggressive bone tumor, which primarily affects children and adolescents, with a high rate of recurrence and metastasis. The standard treatment for children with osteosarcoma is a combination of chemotherapy and surgical removal of the tumor, often requiring partial limb amputation. The 5-year survival rate for children with metastases at diagnosis is less than 30%, and sadly, there have been no new therapies for treating osteosarcoma in over 30 years.

Background

Background


Neuroblastoma (NB) is one of the most common solid tumors of childhood. Despite multimodality therapy, nearly half of patients with high-risk neuroblastoma will die of this disease. High-risk neuroblastoma typically has many DNA copies of the MYCN gene. I recently identified a group of six proteins which work together to form a network to drive neuroblastoma. Disrupting any one of these proteins causes all to be lost and the tumor cells to die. Unfortunately, there is no known way to target MYCN or these other proteins right now.

Pages